Abstract: Disclosed is a novel vaccine formulation for prevention against Bluetongue virus infection in domestic and wild ruminants, cattle, goats, sheep, pigs, and any other mammals for commercial use. The antigen present in the vaccine is an inactivated antigen comprising 5 different serotypes of Bluetongue virus, thereby making a pentavalent vaccine formulation against Bluetongue virus infections. Also disclosed are method of adaptation of Bluetongue virus in suspension culture upto 2000 liters industrial size bioreactors, and inactivation techniques for preparation of the given vaccine formulation with the presence of suitable adjuvants and preservatives.